Energenesis Biomedical Co., Ltd, a clinical-stage biotech company developing therapies aimed at restoring cellular energy, has announced that it will showcase clinical application data for its investigational treatment ENERGI-F703DFU at the European Wound Management Association 2026 Annual Conference, taking place in Bremen from May 5–7, 2026.

As part of EWMA 2026, the company will deliver a presentation titled “ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foot Ulcers — Clinical Case Sharing.” The session is set for Wednesday, May 6, 2026, between 14:35 and 14:50 CEST during the New Tech Industry Symposium at the EWMA Arena. During the presentation, Energenesis will highlight real-world clinical case experiences illustrating how ENERGI-F703DFU may help accelerate wound closure and enhance recovery in patients suffering from chronic diabetic foot ulcers that are resistant to healing.

We are committed to advancing health equity for patients throughout the cancer care journey. Through our Gilead Oncology Grant, we are providing $3.15 million to support 22 organizations in the U.S. that offer resources for individuals impacted by breast cancer.

Click here to know more.

Gilead Sciences, Inc. is a biopharmaceutical company focused on research, discovery, development, and commercialization of innovative treatments for unmet medical needs. The organization aims to transform and streamline care for individuals facing life-threatening diseases globally. Gilead operates in over 35 countries and is headquartered in Foster City, California.